This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Funding For AIDS Drugs Not Included In Senate Spending Bill

WILL FORCE STATES TO DISENROLL CURRENT ADAP CLIENTS

WASHINGTON, March 19, 2013 /PRNewswire-USNewswire/ -- In an unprecedented action by the federal government, the spending bill about to be passed by the United States Senate does not include funding needed to continue lifesaving medications to nearly 8,000 low-income people with HIV.  As part of the bill that will fund the federal government through the end of September, both the House of Representatives and the Senate have failed to continue $35 million for the AIDS Drug Assistance Program (ADAP). The spending bill also failed to continue $10 million for clinical medical care provided through Part C of the Ryan White Program.

(Logo: http://photos.prnewswire.com/prnh/20110412/DC82138LOGO)

"While we have faced severe waiting lists for people wanting to take medications in the past," said Carl Schmid, Deputy Executive Director of The AIDS Institute, "failure to provide funding for existing patients is a dangerous unprecedented action by the U.S government."  Once a patient begins antiretroviral treatment, the drugs must be taken every day without interruption or the person can quickly become ill. Resistance to medications can occur, even with a single missed dose, leading to serious health complications and higher health costs.   

President Obama increased funding for ADAP on World AIDS Day, 2011 in response to the growing wait lists and at the urging of several Members of Congress.  Earlier House and Senate versions of the FY13 spending bills continued this money, and even included significant increases to address the eight percent growth in clients ADAP experienced last year. 

Senate Appropriations Subcommittee Chairman Tom Harkin attempted to address the ADAP funding cut with an amendment that would have resolved this issue, among other things.  Unfortunately, it failed on a party-line vote on the Senate floor. Without the $35 million continuation  in ADAP funding, states such as Alabama, Florida, Georgia, Illinois, Nebraska, Tennessee and several others will likely stop providing medications to many ADAP clients.

"We hope that before the bill is finalized and sent to the President, Congress will see fit to find a way to continue this funding to avoid any interruptions in lifesaving care and treatment  With sequestration and discussion of further budget cuts, continuation of this funding is an absolute necessity," concluded Schmid.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs